Style | Citing Format |
---|---|
MLA | Raoufinejad K, et al.. "Efficacy and Safety of Permethrin 5% Topical Gel Vs. Placebo for Rosacea: A Double-Blind Randomized Controlled Clinical Trial." Journal of the European Academy of Dermatology and Venereology, vol. 30, no. 12, 2016, pp. 2105-2117. |
APA | Raoufinejad K, Mansouri P, Rajabi M, Naraghi Z, Jebraeili R (2016). Efficacy and Safety of Permethrin 5% Topical Gel Vs. Placebo for Rosacea: A Double-Blind Randomized Controlled Clinical Trial. Journal of the European Academy of Dermatology and Venereology, 30(12), 2105-2117. |
Chicago | Raoufinejad K, Mansouri P, Rajabi M, Naraghi Z, Jebraeili R. "Efficacy and Safety of Permethrin 5% Topical Gel Vs. Placebo for Rosacea: A Double-Blind Randomized Controlled Clinical Trial." Journal of the European Academy of Dermatology and Venereology 30, no. 12 (2016): 2105-2117. |
Harvard | Raoufinejad K et al. (2016) 'Efficacy and Safety of Permethrin 5% Topical Gel Vs. Placebo for Rosacea: A Double-Blind Randomized Controlled Clinical Trial', Journal of the European Academy of Dermatology and Venereology, 30(12), pp. 2105-2117. |
Vancouver | Raoufinejad K, Mansouri P, Rajabi M, Naraghi Z, Jebraeili R. Efficacy and Safety of Permethrin 5% Topical Gel Vs. Placebo for Rosacea: A Double-Blind Randomized Controlled Clinical Trial. Journal of the European Academy of Dermatology and Venereology. 2016;30(12):2105-2117. |
BibTex | @article{ author = {Raoufinejad K and Mansouri P and Rajabi M and Naraghi Z and Jebraeili R}, title = {Efficacy and Safety of Permethrin 5% Topical Gel Vs. Placebo for Rosacea: A Double-Blind Randomized Controlled Clinical Trial}, journal = {Journal of the European Academy of Dermatology and Venereology}, volume = {30}, number = {12}, pages = {2105-2117}, year = {2016} } |
RIS | TY - JOUR AU - Raoufinejad K AU - Mansouri P AU - Rajabi M AU - Naraghi Z AU - Jebraeili R TI - Efficacy and Safety of Permethrin 5% Topical Gel Vs. Placebo for Rosacea: A Double-Blind Randomized Controlled Clinical Trial JO - Journal of the European Academy of Dermatology and Venereology VL - 30 IS - 12 SP - 2105 EP - 2117 PY - 2016 ER - |